activity of imipenem/relebactam and comparators against isolates collected in Brazilian hospitals according to results from the Study for Monitoring Antimicrobial Resistance Trends, 2020-2021.

The Study for Monitoring Antimicrobial Resistance Trends (SMART) surveillance program tested imipenem/relebactam (IMR) and comparators against a total of 2,258 non-duplicate clinical isolates of and ) collected across six Brazilian cities during 2020-2021. Antimicrobial susceptibility was determined by the Clinical and Laboratory Standards Institute (CLSI) reference broth microdilution method and interpreted following Brazilian Committee on Antimicrobial Susceptibility (BrCAST)/European Committee on Antimicrobial Susceptibility Testing (EUCAST) breakpoints. isolates were screened for β-lactamase genes () by sequencing. The most frequent isolates identified among were ( = 471; 20.9%) and ( = 453; 20.1%). Susceptibility testing showed that >99% of isolates were susceptible to colistin ([COL], = 470; 99.8%), meropenem ([MEM], = 468; 99.4%), IMR ( = 468; 99.4%), and ceftazidime/avibactam ([CZA], = 468; 99.4%), whereas a high proportion of multidrug-resistant (MDR) isolates were susceptible to COL ( = 69; 98.6%), CZA ( = 67; 95.7%), MEM ( = 67; 95.7%), IMR ( = 67; 95.7%), and amikacin ([AMK], = 66; 94.3%). Overall, isolates were most susceptible to CZA ( = 414; 91.4%) and IMR ( = 411; 90.7%) and over 86.0% of MDR isolates were susceptible to CZA ( = 268; 87.3%) and IMR ( = 265; 86.3%). This study reported that IMR was one of the most effective β-lactam-β-lactamase inhibitor combinations tested and demonstrated comparable activity to CZA and higher activity than COL against both the species tested.IMPORTANCEAs new mechanisms of antibiotic resistance continue to emerge, especially with the rise of carbapenem resistance, this study emphasizes the importance of assessing the current landscape of antimicrobial resistance to identify optimal therapeutic approaches. In this way, the publication of national data is significant for understanding local epidemiology to evaluate new drugs and make the best choice among the antimicrobials available in the hospital environment, both for critically ill patients with resistant bacterial infections.